Posted on

What Caught Our Attention in the Investment World? – Week of September 6-9, 2022

By Kuldip K. Ambastha The stock of Regeneron Pharmaceuticals, Inc. (REGN), a biotechnology company with a portfolio of medicines for individuals with serious diseases, increased in price by +18.8% per share on the trading day of Thursday, September 8, 2022. Eylea (aka: aflibercept), an anti-blindness eye medication, was the cause of this price run-up, because …

Continue reading “What Caught Our Attention in the Investment World? – Week of September 6-9, 2022”

Posted on

What Caught Our Attention in the Investment World? – Week of August 16-20, 2021

By Kuldip K. Ambastha Sonoma Pharmaceuticals Inc. (SNOA) is a specialty pharmaceutical company focused on conditions which could be treated using stabilized hypochlorous acid (HOCl or HClO) in various ways. The company’s stock had a volatile end for this past trading week, with a gain of +50.6% on Thursday, August 19, 2021 followed by a …

Continue reading “What Caught Our Attention in the Investment World? – Week of August 16-20, 2021”

Posted on

What Caught Our Attention in the Investment World? – Week of December 9-13, 2019

By Kuldip K. Ambastha and Anil K. Ambastha On Monday, December 9, 2019, big news emerged in the mergers & acquisitions field in terms of Merck & Co., Inc. (MRK) buying ArQule, Inc. (ARQL) and Sanofi SA (SNY) buying Synthorx Inc. (THOR). Both Merck and Sanofi bought the smaller companies to enhance their capabilities in …

Continue reading “What Caught Our Attention in the Investment World? – Week of December 9-13, 2019”

Posted on

What Caught Our Attention in the Investment World? – Week of December 2-6, 2019

By Kuldip K. Ambastha and Anil K. Ambastha On Thursday, December 5, 2019, there was “a tale of two cities,” to quote Charles Dickens. In the biotech arena, SAGE (Sage Therapeutics, Inc.) and AUPH (Aurinia Pharmaceuticals Inc.) were big movers. Sage Therapeutics delivered -59.7% for the day, while Aurinia Pharmaceuticals returned 78.8%. SAGE-217 is a …

Continue reading “What Caught Our Attention in the Investment World? – Week of December 2-6, 2019”

Posted on

What Caught Our Attention in the Investment World? – Week of September 9-13, 2019

By Kuldip K. Ambastha and Anil K. Ambastha Acadia Pharmaceuticals Inc. (ACAD) is a biopharmaceutical company which has Nuplazid (aka: pimavanserin) in its product pipeline. Nuplazid has been used by individuals suffering from Parkinson’s disease-linked psychosis. Acadia has now analyzed Nuplazid in relation to individuals suffering from dementia-related psychosis. Currently, no approved drugs exist in …

Continue reading “What Caught Our Attention in the Investment World? – Week of September 9-13, 2019”